Mounjaro (Tirzepatide)

Information regarding the availability of weight-loss injections on the NHS

Tirzepatide, for the treatment of overweight and obesity is the first pharmacotherapy to be approved by NICE to be made available from a primary care setting and will be made available from the 1st July. 

Cohort 1

Year 1 (2025-2026) - Duration 12 months

Comorbidities

At  least 4 out of the 5 following conditions:

1. Hypertension,
2. Dyslipidaemia,
3. Obstructive sleep apnoea,
4. Cardiovascular disease,
5. 5. Type 2 diabetes mellitus

BMI

With a BMI of 40kg/m2 or above (or 37.5kg/m2 for people from a South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic background).

• We have identified the patients who are eligible for the NHS weight loss management service, and we will be contacting them directly to discuss further
• If you do not meet the above criteria, we will not be able to prescribe weight loss injections. 

Published: Jun 25, 2025